Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lexicon Pharmaceuticals stock

Learn how to easily invest in Lexicon Pharmaceuticals stock.

Lexicon Pharmaceuticals Inc is a biotechnology business based in the US. Lexicon Pharmaceuticals shares (LXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Lexicon Pharmaceuticals employs 87 staff and has a trailing 12-month revenue of around $109,000.

How to buy shares in Lexicon Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LXRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Lexicon Pharmaceuticals stock price (NASDAQ: LXRX)

Use our graph to track the performance of LXRX stocks over time.

Lexicon Pharmaceuticals shares at a glance

Information last updated 2022-10-02.
Latest market close$2.56
52-week range$1.31 - $6.33
50-day moving average $2.75
200-day moving average $2.58
Wall St. target price$13.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.61

Buy Lexicon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lexicon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lexicon Pharmaceuticals price performance over time

Historical closes compared with the close of $2.56 from 2022-10-04

1 week (2022-09-29) 6.22%
1 month (2022-09-06) -0.39%
3 months (2022-07-06) -2.66%
6 months (2022-04-06) 5.35%
1 year (2021-10-05) -47.22%
2 years (2020-10-06) 77.78%
3 years (2019-10-04) 3.46
5 years (2017-10-05) 12.03

Lexicon Pharmaceuticals financials

Revenue TTM $109,000
Gross profit TTM $-54,748,000
Return on assets TTM -42.11%
Return on equity TTM -93.04%
Profit margin 0%
Book value $0.47
Market capitalisation $452.9 million

TTM: trailing 12 months

Lexicon Pharmaceuticals share dividends

We're not expecting Lexicon Pharmaceuticals to pay a dividend over the next 12 months.

Have Lexicon Pharmaceuticals's shares ever split?

Lexicon Pharmaceuticals's shares were split on a 1:7 basis on 21 May 2015. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lexicon Pharmaceuticals shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Lexicon Pharmaceuticals shares which in turn could have impacted Lexicon Pharmaceuticals's share price.

Lexicon Pharmaceuticals share price volatility

Over the last 12 months, Lexicon Pharmaceuticals's shares have ranged in value from as little as $1.31 up to $6.33. A popular way to gauge a stock's volatility is its "beta".

LXRX.US volatility(beta: 1.43)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lexicon Pharmaceuticals's is 1.4251. This would suggest that Lexicon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Lexicon Pharmaceuticals overview

Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas. .

Frequently asked questions

What percentage of Lexicon Pharmaceuticals is owned by insiders or institutions?
Currently 1.028% of Lexicon Pharmaceuticals shares are held by insiders and 77.943% by institutions.
How many people work for Lexicon Pharmaceuticals?
Latest data suggests 87 work at Lexicon Pharmaceuticals.
When does the fiscal year end for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals's fiscal year ends in December.
Where is Lexicon Pharmaceuticals based?
Lexicon Pharmaceuticals's address is: 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
What is Lexicon Pharmaceuticals's ISIN number?
Lexicon Pharmaceuticals's international securities identification number is: US5288723027
What is Lexicon Pharmaceuticals's CUSIP number?
Lexicon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 528872104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site